15 December 2022
Russian pharmaceutical company NovaMedica (RUSNANO portfolio company) has developed and registered two innovative drugs to combat disorders of the central nervous system (CNS): Difendum®[1] for pain relief and Levroso® Long[1] for insomnia therapy. The products will be manufactured in Russia by the Technology Center NovaMedica Innotech (100% subsidiary of NovaMedica).
27 September 2022
Top managers of NovaMedica are in the TOP-1000 Russian Managers list of business leaders created by the Russian Managers Association and Kommersant Publishing House. For the third time, NovaMedica CEO Elena LITVINOVA was named one of the best CEOs in pharmaceutics. Tatiana ALBAUT, PR Director of NovaMedica, also made it to the TOP-1000.
GXP News Contest takes competitors to R&D Center
25 August 2022
R&D Center NovaMedica Innotech welcomed finalists of the contest among authors of opinion columns on drug development in Russia Anastasia Novikova, Alexey Veselkov and Maria Lobanova. The contest was organized by the leading website on pharmaceutics GxP News.
R&D Center NovaMedica Innotech becomes industrial partner of the Eurasian Academy of Good Practices
17 June 2022
R&D Center NovaMedica Innotech (subsidiary of the pharma company NovaMedica, RUSNANO portfolio asset) and the independent non-profit organization Eurasian Academy of Good Practices signed the Memorandum of Cooperation aiming to develop competences of the Russian pharmaceutics professionals.
12 May 2022
R&D Center NovaMedica Innotech has celebrated its 5th anniversary. The Center was created during implementation of the R&D strategy of its parent company NovaMedica (RUSNANO’s portfolio asset), which is 10 years old this year. Innotech does projects under NovaMedica’s own R&D program and offers to its partners services in development of new drugs and in contract manufacturing of solid dosage forms.
NovaMedica Launches Own Innovative Drug for the Treatment of Alzheimer’s Disease
19 April 2022
Russian pharmaceutical company NovaMedica (investment project of RUSNANO) has developed and registered an innovative combination of Donepezil and Memantine molecules, which are the basic therapy for dementia associated with Alzheimer's disease. The drug is registered under the name Mioreol®[1]. This is the first such combination in the Russian market and in the markets of the EAEU and Europe.
Merry Christmas and Happy New Year!
29 December 2021
Dear friends!
We wish you ghappiness and health in the coming year! May it bring peace, prosperety and success! Congratulations!
Timofey Petrov appointed Director General of Innotech
25 October 2021
Russian pharmaceutical company NovaMedica announces appointment of Timofey PETROV as the head of the R&D Center NovaMedica Innotech (subsidiary of NovaMedica).
Innotech renews manufacturing license
21 September 2021
R&D Center NovaMedica Innotech has successfully passed the audit of the Ministry of Industry and Trade and received a renewed and extended manufacturing license for production of pharmaceutical drugs, which creates new contracting opportunities and, in addition to the already existing services, allows carrying out primary and secondary packaging of biological products.
NovaMedica signed an agreement with Bayer on transfer of exclusive rights to its product
31 May 2021
Russian pharmaceutical company NovaMedica (part of the RUSNANO portfolio) and the corporation Bayer signed an agreement to provide Bayer with an exclusive license to commercialization of an innovative product developed by NovaMedica, including its manufacturing and promotion.
Merry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Enhancing spectroscopy analysis with machine learning
03 February 2025
The production of new Russian “super antibiotic” to begin in Novosibirsk
03 February 2025
A Russian company has started producing 4 veterinary vaccines
31 January 2025
The government held its first meeting on the “New technologies for preserving health” project
31 January 2025